Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 5, 2007, Pages 505-514

  Tarhini, Ahmad A ^a   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTAGONIST; DACARBAZINE; EXEMESTANE; MONOCLONAL ANTIBODY; MONOCLONAL IMMUNOGLOBULIN G2 ANTIBODY; PF 3512676; SUNITINIB; TEMOZOLOMIDE; TREMELIMUMAB; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ASTHMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLITIS; DERMATITIS; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; DRUG WITHDRAWAL; EYE DISEASE; FATIGUE; HUMAN; HYPOTHYROIDISM; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NONHUMAN; PANCREATITIS; PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URTICARIA; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CANCER VACCINES; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOGLOBULIN G; MELANOMA;

EID: 35348812574     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. 30394 CTLA-4 is a second receptor for the B cell activation antigen B7. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA J EXP MED 1991 174 3 561-569
2. 316199 Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP PROC NATL ACAD SCI USA 1997 94 15 8099-8103
3. 427696 High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U J CLIN ONCOL 2001 19 9 2370-2380
4. 438730 Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH J CLIN ONCOL 1996 14 1 7-17
5. 511848 Cancer regression and autoimmunity induced by cytotoxic T lymphocyte associated antigen 4 blockade in patients with metastatic melanoma. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE et al PROC NATL ACAD SCI USA 2003 100 14 8372-8377
6. 519356 The emerging role of CTLA4 as an immune attenuator. Thompson CB, Allison JP IMMUNITY 1997 7 4 445-450
7. 519359 Enhancement of antitumor immunity by CTLA4 blockade. Leach DR, Krummel MF, Allison JP SCIENCE 1996 271 5256 1734-1736
8. 529855 CP-675,206 anti-CTLA4 antibody clinical candidate enhances IL-2 production in cancer patient T-cells in vitro regardless of tumor type or stage of disease. Canniff PC, Donovan CB, Burkwit JJ, Bruns MJ, Bedian V, Bernstein SH, Hanson DC PROC AM ASSOC CANCER RES 2004 45 Abs 709 • This in vitro study showed that tremelimumab induced robust cytokine production in T-cells from both normal donors and a wide range of cancer patients, supporting the continued preclinical and clinical development of the drug.
9. 531134 Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. Hanson DC, Canniff PC, Primiano MJ, Donovan CB, Gardner JP, Natoli EJ, Morgan RW, Mather RJ, Singleton DH, Hermes PA, Neveu MJ et al PROC AM ASSOC CANCER RES 2004 45 Abs 3802
10. 541898 High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C et al J CLIN ONCOL 1999 17 7 2105-2116
11. 543529 Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. Camacho LH, Ribas A, Glaspy JA, Lopez-Berestein G, Reuben JM, Parker C, Seja E, Comin-Anduix B, Bulanhagui C, Gomez-Navarro J J CLIN ONCOL 2004 22 Abs 2505 • The first clinical trial of tremelimumab demonstrating that tremelimumab was safe and well tolerated and showed promising efficacy in patients with metastatic melanoma.
12. 586079 CTLA-4-mediated inhibition of early events of T cell proliferation. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP J IMMUNOL 1999 162 10 5813-5820
13. 598079 Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma. Ribas A, Bozon VA, Lopez-Berestein G, Pavlov D, Reuben JM, Parker CA, Seja E, Glaspy JA, Gomez-Navarro J, Camacho LH PROC AM SOC CLIN ONCOL 2005 24 Abs 7524
14. 604054 Therapy with human monoclonal anti-CTLA-4 antibody, CP-675,206, reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (MM). Reuben JM, Lee BN, Shen DY, Gutierrez C, Hernandez I, Parker CA, Bozon VA, Gomez-Navarro J, Lopez-Berestein G, Camacho LH PROC AM SOC CLIN ONCOL 2005 24 Abs 7505 • This trial suggested that tremelimumab is biologically active in patients with metastatic melanoma and may improve T-cell-mediated immunity in patients experiencing clinical benefit.
15. 612509 Eighth annual targeted therapies for the treatment of breast cancer, Dana Point, CA, USA, 6-9 July 2005. Pusztai L IDDB MEETING REPORT 2005 July 6-9
16. 623970 Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP et al J CLIN ONCOL 2005 23 25 6043-6053
17. 623994 Autoimmunity in a phase I trial of a fully human anti-cytotoxic T lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M et al J CLIN ONCOL 2005 23 4 741-750
18. 645128 Medarex R and D day. Medarex Inc COMPANY PRESENTATION 2005 December 09
19. 645891 Pfizer's revenue and R&D expenses down in 2005. Pfizer Inc PRESS RELEASE 2006 January 19
20. 670811 Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab. Ribas A, Comin-Anduix B, Bozon V, Camacho LH, Bulanhagui C, Jalil J, Seja E, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J J CLIN ONCOL 2006 24 Abs 8033 • This study showed that in patients with tremelimumab-induced immunerelated phenomena and tumor responses, there was no consistent pattern of change in circulating T-cells specific for MART-1. The researchers suggest that the mechanism of antitumor activity of CTLA4 blockage may be better evaluated by studying melanoma antigen-specific T-cells within the tumor.
21. 671037 Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma. Gomez-Navarro J, Sharma A, Bozon V, Bulanhagui C, Pavlov D, Eck S, Ribas A, Camacho LH J CLIN ONCOL 2006 24 Abs 8032 • This analysis established the phase II recommended dose of tremelimumab as 15 mg/kg given every 3 months based on similar efficacy, but an improved safety profile, compared with 10 mg/kg monthly dosing.
22. 671396 Phase I clinical trials of ticilimumab: Tumor responses are sufficient but not necessary for prolonged survival. Bulanhagui CA Ribas, A, Pavlov D, Bozon V, Sharma A, Gomez-Navarro J, Camacho LH J CLIN ONCOL 2006 24 Abs 8036
23. 674291 Medarex receives SPA for pivotal ipilimumab melanoma trial. Medarex Inc PRESS RELEASE 2006 June 19
24. 681758 NCT00257205: Phase 3 trial of CP-675,206 versus either dacarbazine or temozolomide in patients without prior therapy. Pfizer INTERNET SITE 2006 July 25
25. 681759 NCT00312975: Phase 2 randomized study of CP-675,206 or best supportive care immediately after platinum-based therapy for NSCLC. Pfizer INTERNET SITE 2006 July 25
26. 687303 Monoclonal antibodies in cancer - sixth international congress, Washington DC, USA, 18-20 August 2006. IDdb author IDDB MEETING REPORT 2006 August 18-20
27. 745115 Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH CANCER 2006 106 11 2437-2444
28. 745116 Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A et al J CLIN ONCOL 2005 23 35 8968-8977
29. 755047 Medarex and BMS complete enrollment in ipilimumab phase III melanoma trial. Medarex Inc PRESS RELEASE 2007 January 04
30. 796255 Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study. Gomez-Navarro J, Antonia S, Sosman, J, Kirkwood JM, Redman B, Gajewski TF, Pavlov D, Bulanhagui C, Ribas A, Camacho LH J CLIN ONCOL 2007 25 Abs 8524
31. 796262 Phase II trial of extended-dosing temozolomide in patients with melanoma. Rietschel R AM SOC CLIN ONCOL 2007 43 Abs 8531
32. 797045 Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. Ribas A, Antonia S, Sosman J, Kirkwood JM, Redman B, Gajewski TF, Pavlov D, Bulanhagui C, Gomez-Navarro J, Camacho LH AM SOC CLIN ONCOL 2007 25 Abs 3000
33. 797175 A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum. Chung KY, Gore I, Fong L, Venook A, Dorazio P, Healey D, Pavlov D, Saltz LB J CLIN ONCOL 2007 25 Abs 3035
34. 797178 Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206. Antonia S, Sosman J, Kirkwood JM, Redman B, Gajewski TF, Pavlov D, Bulanhagui C, Camacho LH, Ribas A J CLIN ONCOL 2007 25 Abs 3038
35. 799637 Changes in intratumoral immune cell infiltrates, Foxp3 and indoleamine 2, 3-dioxygenase (IDO) expression with the CTLA4 blocking mAb CP-675,206. Ribas A, Donahue TR, Comin-Anduix B, de la Rocha P, Glaspy JA, Economou JS, Gomez-Navarro J, Cochran AJ J IMMUNOTHER 2006 29 6 636
36. 799638 Immunological assays to differentiate clinical responders from non-responders after CTLA4 blockade with CP-675,206. Comin-Anduix B, Lee Y, Jalil J, de la Rocha P, Seja E, Bozon VA, Camacho LH, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A J IMMUNOTHER 2006 29 6 634-635
37. 802955 Clearance of monoclonal antibody (mAb) CP-675,206 by therapeutic plasma exchange (TPE) or plasmapheresis. Sharma A, Bumerts P, Gomez-Navarro J, Pavlov D, Ribas A AM SOC CLIN ONCOL 2007 25 Abs 13515
38. 803573 CD28/B7 system of T cell costimulation. Lenschow DJ, Walunas TL, Bluestone JA ANN REV IMMUNOL 1996 14 233-258
39. 803619 Expression and function of CTLA4 in Th1 and Th2 cells. Alegre ML, Shiels H, Thompson CB, Gajewski TF J IMMUNOL 1998 161 7 3347-3356.
40. 803628 Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade immunotherapy. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB PROC NATL ACAD SCI USA 1999 96 26 15074-15079
41. 803641 CTLA-4: New insights into its biological function and use in tumor immunotherapy. Egen JG, Kuhns MS, Allison JP NAT IMMUNOL 2002 3 7 611-618
42. 803644 Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Egen JG, Allison JP IMMUNITY 2002 16 1 23-35
43. 803645 High- and low-dose interferon α-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH J CLIN ONCOL 2000 18 12 2444-2458
44. 803648 CTLA4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK J IMMUNOL 1996 157 4 1333-1336
45. 803655 CTLA4: A negative regulator of autoimmune disease. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA J EXP MED 1996 184 2 783-788
46. 803656 Specific blockade of CTLA4/B7 interactions results in exacerbated clinical and histological disease in an actively-induced model of experimental encephalomyelitis. Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JP J NEUROIMMUNOL 1997 73 1-2 57-62
47. 803660 Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) regulates the unfolding of autoimmune diabetes. Luhder F, Hoglund P, Allison JP, Benoist C, Mathis D J EXP MED 1998 187 3 427-432
48. 803661 The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFNγ. Paradis TJ, Floyd E, Burkwit J, Cole SH, Brunson B, Elliott E, Gilman S, Gladue RP CANCER IMMUNOL IMMUNOTHER 2001 50 3 125-133
49. 803662 CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice. Sabel MS, Hess SD, Egilmez NK, Conway TF Jr, Chen FA, Bankert RB CANCER IMMUNOL IMMUNOTHER 2005 54 10 944-952
50. 803664 Metabolic properties of IgG subclasses in man. Morell A, Terry WD, Waldmann TA J CLIN INVEST 1970 49 4 673-680
51. 803665 Antibody pharmacokinetics and pharmacodynamics. Lobo ED, Hansen RJ, Balthasar JP J PHARM SCI 2004 93 11 2645-2668
52. 803869 CTLA-4 blockade: Unveiling immune regulation. Dranoff G J CLIN ONCOL 2005 23 4 662-664
53. 803924 Prognostic significance of autoimmunity during treatment of melanoma with interferon. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C et al N ENGL J MED 2006 354 7 709-718
54. 803926 Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA J CLIN ONCOL 2001 19 15 3477-3482
55. 809047 Building momentum: Pfizer's oncology franchise at ASCO. Pfizer Inc COMPANY PRESENTATION 2007 June 04
56. 812896 The role of CTLA4 in the regulation of T cell immune responses. McCoy KD, Le Gros G IMMUNOL CELL BIOL 1999 77 1 1-10
57. 812897 CD28 and CTLA4 have opposing effects on the response of T cells to stimulation. Krummel MF, Allison JP J EXP MED 1995 182 2 459-465
58. 812923 A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon α-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM PROC AM SOC CLIN ONCOL 2003 22 708 Abs 2847
59. 813424 Synthesis of tremelimumab. Pfizer Inc COMPANY COMMUNICATION 2007 May 23
60. 814370 NCT00471887: Ticilimumab (CP-675,206) in treating patients with stage IIIC or stage IV melanoma. National Cancer Institute CLINICALTRIALS.GOV 2007 July 19
61. 814372 NCT00372853: Dose-finding study of CP-675,206 and SU011248 in patients with metastatic renal cell carcinoma not previously treated. Pfizer Inc CLINICALTRIALS.GOV 2007 July 19
62. 814592 Drug development pipeline: Tremelimumab. Pfizer Inc COMPANY COMMUNICATION 2007 June 27
63. 814652 NCT00312975; Phase 2 randomized study of CP-675,206 or best supportive care immediately after platinum-based therapy for NSCLC. Pfizer CLINICALTRIALS.GOV 2007 June 01
64. 815061 Immunotherapy of renal cell carcinoma. Gouttefangeas C, Stenzl A, Stevanovic S, Rammensee HG CANCER IMMUNOL IMMUNOTHER 2007 56 1 117-128
65. 815318 Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3, 5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agent. Stevens MF, Hickman JA, Stone R, Gibson NW, Baig GU, Lunt E, Newton CG J MED CHEM 1984 27 2 196-201
66. 815319 Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA et al CANCER RES 1987 47 22 5846-5852
67. 815323 Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B et al J CLIN ONCOL 2000 18 1 158-166
68. 815334 Cutaneous melanoma: Available therapy for metastatic disease. Tarhini AA, Agarwala SS DERMATOL THER 2006 19 1 19-25
69. 815335 Control of regulatory T-cell development by the transcription factor Foxp3. Hori S, Nomura T, Sakaguchi S SCIENCE 2003 299 5609 1057-1061
70. 815337 The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. Weber JS MELANOMA RES 2006 16 5 379-383
71. 815343 Vitiligo-like lesions following immunotherapy with IFNα and IL-2 in melanoma patients. Scheibenbogen C, Hunstein W, Keilholz U EUR J CANCER 1994 30A 8 1209-2111
72. 815345 Endocrine involvement in immunotherapy. Tartour E, Schlumberger M, Dorval T, Baudin E, Fridman WH ANN ENDOCRINOL 1995 56 2 143-148
73. 815860 Update on immunotherapy for melanoma. Ribas A J NATL COMPR CANC NETW 2006 4 7 687-694
74. 815864 Systemic chemotherapy and biochemotherapy. Buzaid AC, Bedikian A, Houghton A CUTANEOUS MELANOMA Balch CM, Houghton AN, Sober AJ, Soong SJ (Eds), Quality Medical Publishing Inc, St Louis MO, USA 1998 405-418
75. 822144 Tremelimumab (CP-675,206), a cytotoxic T-lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bernstein SH, Canniff PC, Sharma A, Gomez-Navarro J ONCOLOGIST 2007 12 7 873-883
76. 822170 Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A AM J OPHTHALMOL 2007 143 6 958-969
77. 823810 Principles of cancer management: Biologic therapy. Rosenberg SA In: CANCER: PRINCIPLES PRACTICE ONCOL, 7th Edition, Devita VT, Hellman S, Rosenberg SA (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA 2005 307-333
78. 825907 Pfizer. LeCroy J, Shankman SB NATEXIS BLEICHROEDER INC 2007 July 17
79. 825908 Pfizer and Abbott. Arnold AJ, Faerm M CREDIT SUISSE 2007 July 19